ECSP21082195A - Formas sólidas de un inhibidor de glyt1 - Google Patents

Formas sólidas de un inhibidor de glyt1

Info

Publication number
ECSP21082195A
ECSP21082195A ECSENADI202182195A ECDI202182195A ECSP21082195A EC SP21082195 A ECSP21082195 A EC SP21082195A EC SENADI202182195 A ECSENADI202182195 A EC SENADI202182195A EC DI202182195 A ECDI202182195 A EC DI202182195A EC SP21082195 A ECSP21082195 A EC SP21082195A
Authority
EC
Ecuador
Prior art keywords
solid forms
inhibitor
glyt1 inhibitor
glyt1
glycine transporter
Prior art date
Application number
ECSENADI202182195A
Other languages
English (en)
Inventor
Peter Sieger
Joe Ju Gao
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP21082195A publication Critical patent/ECSP21082195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se divulgan formas sólidas de un inhibidor del transportador de glicina-1 (GlyT1). La invención también se refiere a métodos para fabricar estas formas sólidas, composiciones farmacéuticas que comprenden estas formas sólidas y su uso para afecciones médicas que responden al tratamiento con un inhibidor del transportador de glicina-1.
ECSENADI202182195A 2019-05-01 2021-11-17 Formas sólidas de un inhibidor de glyt1 ECSP21082195A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01

Publications (1)

Publication Number Publication Date
ECSP21082195A true ECSP21082195A (es) 2021-12-30

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202182195A ECSP21082195A (es) 2019-05-01 2021-11-17 Formas sólidas de un inhibidor de glyt1

Country Status (25)

Country Link
US (2) US11447474B2 (es)
EP (1) EP3962911A1 (es)
JP (2) JP7513349B2 (es)
KR (1) KR20220004174A (es)
CN (1) CN113784966B (es)
AR (1) AR118839A1 (es)
AU (1) AU2020266566B2 (es)
BR (1) BR112021020883A2 (es)
CA (1) CA3138288A1 (es)
CL (2) CL2021002837A1 (es)
CO (1) CO2021014260A2 (es)
CR (1) CR20210545A (es)
DO (1) DOP2021000224A (es)
EA (1) EA202192925A1 (es)
EC (1) ECSP21082195A (es)
IL (1) IL287630A (es)
JO (1) JOP20210295A1 (es)
MA (1) MA55801A (es)
MX (1) MX2021013341A (es)
PE (1) PE20212263A1 (es)
PH (1) PH12021552741A1 (es)
SG (1) SG11202111972YA (es)
TW (1) TW202106680A (es)
UA (1) UA129159C2 (es)
WO (1) WO2020223419A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
UA129159C2 (uk) * 2019-05-01 2025-01-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
BR112022026698A2 (pt) * 2020-08-13 2023-02-23 Boehringer Ingelheim Int Tratamento da deficiência cognitiva associada à esquizofrenia
CA3195702A1 (en) * 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking
WO2025140479A1 (zh) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Iclepertin的晶型及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
CN101838271A (zh) * 2003-10-14 2010-09-22 辉瑞产品公司 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物
CA2745690A1 (en) * 2008-12-04 2010-06-10 Evgeny Zlotinikov Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
WO2010078348A1 (en) * 2008-12-29 2010-07-08 Vanderbilt University 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US10919891B2 (en) * 2017-04-27 2021-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
UA129159C2 (uk) * 2019-05-01 2025-01-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1
BR112022026698A2 (pt) * 2020-08-13 2023-02-23 Boehringer Ingelheim Int Tratamento da deficiência cognitiva associada à esquizofrenia
CA3195702A1 (en) * 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking

Also Published As

Publication number Publication date
PH12021552741A1 (en) 2022-07-11
JP7513349B2 (ja) 2024-07-09
CN113784966A (zh) 2021-12-10
JP2024100792A (ja) 2024-07-26
CO2021014260A2 (es) 2021-10-29
CN113784966B (zh) 2024-07-19
US11447474B2 (en) 2022-09-20
UA129159C2 (uk) 2025-01-29
CA3138288A1 (en) 2020-11-05
CL2024000829A1 (es) 2024-09-27
DOP2021000224A (es) 2021-12-15
AU2020266566B2 (en) 2025-11-06
MA55801A (fr) 2022-03-09
US20200347041A1 (en) 2020-11-05
NZ781254A (en) 2025-03-28
JP7714727B2 (ja) 2025-07-29
JOP20210295A1 (ar) 2023-01-30
KR20220004174A (ko) 2022-01-11
AU2020266566A1 (en) 2021-11-11
BR112021020883A2 (pt) 2022-04-19
PE20212263A1 (es) 2021-11-29
EA202192925A1 (ru) 2022-03-23
AR118839A1 (es) 2021-11-03
JP2022530630A (ja) 2022-06-30
WO2020223419A1 (en) 2020-11-05
TW202106680A (zh) 2021-02-16
IL287630A (en) 2021-12-01
CR20210545A (es) 2021-12-23
SG11202111972YA (en) 2021-11-29
EP3962911A1 (en) 2022-03-09
MX2021013341A (es) 2021-11-17
CL2021002837A1 (es) 2022-07-29
US20220332710A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
ECSP21082195A (es) Formas sólidas de un inhibidor de glyt1
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
MY202765A (en) Triesters of cyclohexanetripropionic acid
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MX2025009986A (es) Metodos para preparar composiciones proteicas estables
MX2022002120A (es) Almohadilla que comprende un elemento de presion.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2020001885A (es) Formulaciones de daptomicina.
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
PE20180691A1 (es) Variantes de il-37
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
EA202191403A1 (ru) Композиция с высокой концентрацией белка
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
BR112017018618A2 (pt) odorizante de osmanthus
EA202192149A1 (ru) Способ получения растительных материалов со сниженной вариабельностью
MX2016012314A (es) Analagos de apelina ciclicos.
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação